Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion type Assertion NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_head.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion description "[To evaluate the suitability of colorectal cancer (CRC) tissue for these treatment approaches and to find a possible link to pretherapeutic conditions of other targeted strategies, we compared neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutational status in primary and metastatic CRC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_provenance.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion evidence source_evidence_literature NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_provenance.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion SIO_000772 25337237 NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_provenance.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion wasDerivedFrom befree-2016 NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_provenance.
- NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_assertion wasGeneratedBy ECO_0000203 NP1231551.RAXI_hghmXlHdoWZnXEUrCav_OpzKerU4wRXrXmyKfiJ0130_provenance.